Zacks16h agoneutral
Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
319last 24h
2138last 7d
381● bullish (7d)
185● bearish (7d)
204publishers
Motley Fool14d agobullish
AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now?AbbVie still looks like a compelling buy at its all-time high.
Insider Monkey16d agoneutral
Abbott (ABT) Raised Its Profit Forecast. What’s Driving Its Growth?Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Let’s dive deeper […]
Insider Monkey65d agobullish
Goldman Sachs Maintains Buy Rating on Abbott Laboratories (ABT) StockAbbott Laboratories (NYSE:ABT) is one of the Best Blue Chip Stocks Under $100 to Buy Now. On May 27, analyst David Roman from Goldman Sachs maintained a “Buy” rating on the company’s stock and reduced the price objective to $113.00 from $121.00. The analyst’s rating is supported by several factors that highlight improvements in fundamentals and an attractive […]